These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The role of phospholipid methylation in 1-methyl-4-phenyl-pyridinium ion (MPP+)-induced neurotoxicity in PC12 cells. Lee ES; Chen H; Charlton CG; Soliman KF Neurotoxicology; 2005 Dec; 26(6):945-57. PubMed ID: 15950286 [TBL] [Abstract][Full Text] [Related]
28. Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson's disease. Fukushima T; Kaetsu A; Lim H; Moriyama M Exp Toxicol Pathol; 2002 Feb; 53(6):469-73. PubMed ID: 11926289 [TBL] [Abstract][Full Text] [Related]
29. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway. Marchetti B; Serra PA; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Cioni S; Gennuso F; Rocchitta G; Desole MS; Mazzarino MC; Miele E; Morale MC Ann N Y Acad Sci; 2005 Dec; 1057():296-318. PubMed ID: 16399902 [TBL] [Abstract][Full Text] [Related]
30. Is Parkinson's disease a homogeneous disorder--what is the burden of Parkinson's disease in India. Ghosh B; Mishra A; Sengupta P J Indian Med Assoc; 2005 Mar; 103(3):146, 148, 150 passim. PubMed ID: 16173291 [TBL] [Abstract][Full Text] [Related]
31. Covalent inhibitors of nicotinamide N-methyltransferase (NNMT) provide evidence for target engagement challenges in situ. Lee HY; Suciu RM; Horning BD; Vinogradova EV; Ulanovskaya OA; Cravatt BF Bioorg Med Chem Lett; 2018 Sep; 28(16):2682-2687. PubMed ID: 29731364 [TBL] [Abstract][Full Text] [Related]
32. High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease. Parsons RB; Smith SW; Waring RH; Williams AC; Ramsden DB Neurosci Lett; 2003 May; 342(1-2):13-6. PubMed ID: 12727306 [TBL] [Abstract][Full Text] [Related]
33. Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Aoyama K; Matsubara K; Kondo M; Murakawa Y; Suno M; Yamashita K; Yamaguchi S; Kobayashi S Neurosci Lett; 2001 Jan; 298(1):78-80. PubMed ID: 11154840 [TBL] [Abstract][Full Text] [Related]
34. Discovery of Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT). Babault N; Allali-Hassani A; Li F; Fan J; Yue A; Ju K; Liu F; Vedadi M; Liu J; Jin J J Med Chem; 2018 Feb; 61(4):1541-1551. PubMed ID: 29320176 [TBL] [Abstract][Full Text] [Related]
35. Parkinson's disease and cancer: insights for pathogenesis from epidemiology . D'Amelio M; Ragonese P; Sconzo G; Aridon P; Savettieri G Ann N Y Acad Sci; 2009 Feb; 1155():324-34. PubMed ID: 19250224 [TBL] [Abstract][Full Text] [Related]
36. Fluorometric assay of rat tissue N-methyltransferases with nicotinamide and four isomeric methylnicotinamides. Sano A; Endo N; Takitani S Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):153-6. PubMed ID: 1533573 [TBL] [Abstract][Full Text] [Related]
37. Genetic and environmental factors in the pathogenesis of Parkinson's disease. Mizuno Y; Shimoda-Matsubayashi S; Matsumine H; Morikawa N; Hattori N; Kondo T Adv Neurol; 1999; 80():171-9. PubMed ID: 10410718 [No Abstract] [Full Text] [Related]
38. Nicotinamide-N-methyltransferase regulates lipid metabolism via SAM and 1-methylnicotinamide in the AML12 hepatocyte cell line. Yoda M; Mizuno R; Izumi Y; Takahashi M; Bamba T; Kawaoka S J Biochem; 2023 Jun; 174(1):89-98. PubMed ID: 37014628 [TBL] [Abstract][Full Text] [Related]
39. Potent Inhibition of Nicotinamide Gao Y; van Haren MJ; Buijs N; Innocenti P; Zhang Y; Sartini D; Campagna R; Emanuelli M; Parsons RB; Jespers W; Gutiérrez-de-Terán H; van Westen GJP; Martin NI J Med Chem; 2021 Sep; 64(17):12938-12963. PubMed ID: 34424711 [TBL] [Abstract][Full Text] [Related]
40. [Study of Parkinson's disease-causing mechanism and development of anti-Parkinson's disease drugs using endogenous substances in brain]. Ohta S Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Feb; 25(1):39-42. PubMed ID: 15796069 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]